Content - EORTC PEARLS

EORTC PEARLS - Anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with lung cancer

For further information about the trial EORTC PEARLS  please visit the ETOP-Website.

Studychair:

Dr. med. Alessandra Curioni Fontecedro, University Hospital Zurich, +41 44 255 89 02

Locations for this trial:

Universitätsspital Basel
Petersgraben 4
0 4031 Basel
Istituto Oncologico della Svizzera Italiana IOSI
Via Ospedale
0 6500 Bellinzona
Inselspital
Freiburgstrasse 8
3010 Bern
Hôpitaux Universitaires de Genève HUG
Rue Gabrielle-Perret-Gentil 4
0 1205 Genève
Centre Hospitalier Universitaire Vaudois CHUV
Rue du Bugnon 46
0 Lausanne
Kantonsspital Luzern
Spitalstrasse
0 6000 Luzern
Kantonsspital St. Gallen
Rorschacher Strasse 95
0 9007 St. Gallen
UniversitätsSpital Zürich
Rämistrasse 100
0 8091 Zürich
Kantonsspital Winterthur
Brauerstrasse 15
0 8401 Winterthur